|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Research fees | |||||
| Milestone payments | |||||
| Royalty revenue | |||||
| Licensing and royalty revenue | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Royalty fees | |||||
| Research and development | |||||
| Sales and marketing | |||||
| Sales, general and administrative | |||||
| Depreciation, amortization, and impairment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (income) expense: | |||||
| Interest income | |||||
| Grants and incentives | |||||
| Other (Note 15) | |||||
| Total other income | |||||
| Loss before income tax | |||||
| Income tax recovery | |||||
| Net loss | |||||
| Foreign currency translation adjustment | |||||
| Comprehensive loss | |||||
| Net loss per share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average common shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...